Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

Dastoli, Stefano; Passante, Maria; Loconsole, Francesco; Mortato, Edoardo; Balato, Anna; Piccolo, Vincenzo; Guarneri, Claudio; Macca, Laura; Provenzano, Eugenio; Valenti, Giancarlo; D’Amico, Domenico; Micali, Giuseppe; Musumeci, Maria Letizia; Palazzo, Giovanni; Foti, Caterina; Romita, Paolo; Fabbrocini, Gabriella; Megna, Matteo; Bennardo, Luigi; Patruno, Cataldo

doi:10.1080/09546634.2023.2200868

Cited by 10 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the safety profile of secukinumab was consistent to that in previously reported real-world studies, and no new safety concerns were identified. 19 , 24 , 33 , 36 , 37 The most common AE was pruritus, which is similar to the earlier reports in Korea. 29 Occurrence of treatment-related AEs was found to be much less than in a real-world study conducted in Japan (9.5% versus 24.2%).…”

Section: Discussionsupporting

confidence: 88%

“…A real-world study conducted in Italy showed a PASI score improvement over a 240-week period of secukinumab treatment, with 99.6% of patient’s achieving PASI <10 at week 24, which showed no patients discontinued the treatment over the long follow-up time in line with other real-world study enrolled across Europe. 37 , 41 In this study, more biologic-naïve patients were included (80.6%) and showed numerically higher reduction in absolute PASI scores from baseline up to week 24 than the biologic-experienced patients. These results are in line with the therapeutic outcomes (PASI, body surface area, Investigator’s Global Assessment, Dermatology Life Quality Index) of patients with psoriasis of other real-world studies conducted in the USA, Italy, and Australia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Kim,

Shin

et al. 2024

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015. Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea. Design: Multicenter, real-world, noninterventional study conducted over 6 years. Methods: Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24. Results: Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts. Conclusion: Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Kim,

Shin

et al. 2024

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…For example, secukinumab is proved effective for treating plaque psoriasis, and real-world studies demonstrate its effectiveness and long-term efficacy in managing this condition. 4 , 5 Real-world studies can significantly inform dermatological decision-making processes. However, real-world studies on secukinumab use in treating EP are scarce.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

Lu¹,

Wang²

2023

CCID

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare and severe type of psoriasis. Common systemic therapies for children with EP include treatment with glucocorticoids, cyclosporine, acitretin, and methotrexate. Although these drugs are effective, they may cause serious side effects to children. Secukinumab has recently demonstrated efficacy in treating plaque psoriasis, but its efficacy in EP children remains unknown. We report a case of a seven-year-old patient who transitioned from generalized pustular psoriasis (GPP) to EP after routine systemic drug treatment. The patient was then treated with secukinumab. The patient’s condition improved noticeably within 48 hours after the first injection. After the fifth injection, she almost completely cleared her skin lesions and achieved Psoriasis Area and Severity Index 90 (PASI 90) scores. During this period, she experienced only one respiratory infection. She completed all 11 doses of secukinumab by October 14, 2022, with no new rash (PASI 100) and no adverse drug reactions. Follow-up observation on March 15, 2023, showed no new rash (PASI 100) and no adverse reactions after medication withdrawal. This case suggests that it may also be effective in treating children with EP.

show abstract

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Malagoli,

Dapavo,

Amerio

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.

show abstract

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

Cited by 10 publications

References 41 publications

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Contact Info

Product

Resources

About